pck2 Antibody

What is PCK2 and what cellular functions has it been implicated in?

PCK2 is a mitochondrial enzyme that catalyzes the conversion of oxaloacetate to phosphoenolpyruvate, playing a key role in gluconeogenesis and energy metabolism. Recent research has revealed PCK2's involvement in:

• Maintaining redox balance in antibody-secreting cells (ASCs) through regulation of glutamine metabolism

• Vascular smooth muscle cell (VSMC) proliferation via the Akt-FoxO-PCK2 pathway

• Cancer cell radioresistance through modulation of ferroptosis sensitivity

• Pancreatic islet cell function in diabetes models

The enzyme typically appears as a ~71 kDa protein in western blot analyses, though molecular weight may vary slightly by species and experimental conditions .

What detection methods work best for PCK2 antibodies?

PCK2 antibodies have been successfully employed in multiple experimental platforms:

For western blotting, PCK2 antibodies perform optimally when membranes are blocked with 5% skimmed milk in TBST for 2 hours at room temperature, followed by overnight incubation with primary antibody at 4°C .

How can I validate PCK2 antibody specificity in my experimental system?

Proper validation of PCK2 antibodies is essential for experimental rigor. Consider these approaches:

• Compare detection against recombinant PCK2 protein as a positive control

• Include PCK2 knockdown samples using validated siRNA sequences (e.g., targeting PCK2-specific regions)

• Verify expression at the mRNA level using RT-PCR with specific primers (forward: 5′-GGG TGC TAG ACT GGA TCT GC-3′ and reverse: 5′-CTG GTT GAC CTG CTC TGT CA-3′)

• Test antibody reactivity in tissues with known PCK2 expression (kidney tissue serves as an excellent positive control)

• Perform multiplexing with housekeeping proteins (β-actin at 48 kDa) to confirm appropriate protein size detection (PCK2 at ~63-71 kDa)

How does PCK2 contribute to intestinal homeostasis and colitis protection?

Recent studies have uncovered a critical role for PCK2 in protecting against colitis by maintaining antibody-secreting cell function. Key research findings include:

• PCK2 loss (globally or B-cell specific) exacerbates dextran sodium sulphate (DSS)-induced colitis in mouse models

• PCK2 deficiency leads to increased IgA antibody-secreting cell (ASC) death and diminished antibody production

• Mechanistically, PCK2 absence diverts glutamine into the TCA cycle, resulting in:

  • Heightened TCA flux and excessive mitochondrial reactive oxygen species (mtROS)

  • Reduced glutamine availability for glutathione (GSH) synthesis

  • Overwhelming oxidative stress that triggers ASC apoptosis

Notably, the mitochondria-targeted antioxidant Mitoquinone (Mito-Q) mitigates the effects of PCK2 deficiency, suggesting therapeutic potential for colitis treatment .

What methods are effective for studying PCK2 in spatially-resolved tissue samples?

Laser Capture Microdissection (LCM) coupled with Capillary Immunoassay provides powerful insights into PCK2 expression in specific tissue regions:

• This method enables protein detection from precisely excised tissue regions as small as 0.125 mm² with 10 μm thickness

• For analyzing PCK2 in Langerhans islets:

  • Islets are pooled until reaching a total section area >0.8 mm²

  • WES buffer (0.5×) with fluorescent master maintains dissected area at 0.05 mm²/μL

  • Anti-PCK2 antibodies at 1:75 dilution combined with anti-β-actin antibodies (1:75)

  • PCK2 signals appear at ~63 kDa, β-actin at ~48 kDa

  • Normalization via PCK2/ACTB peak area ratios enables quantitative comparison

This approach has successfully demonstrated significant PCK2 overexpression in Langerhans islets of rats with long-term diabetes compared to controls .

How does PCK2 regulate vascular smooth muscle cell proliferation?

PCK2 has emerged as a key regulator of vascular smooth muscle cell (VSMC) proliferation and neointimal hyperplasia:

• PCK2 knockdown via siRNA significantly attenuates platelet-derived growth factor (PDGF)-induced VSMC proliferation

• RNA sequencing of PCK2-silenced human VSMCs revealed the Akt-FoxO-PCK2 pathway's involvement in proliferation, specifically through:

  • Akt2 and Akt3 signaling components

  • FoxO1 and FoxO3 transcription factors

• Neointimal hyperplasia is attenuated in wire-injured femoral arteries of Pck2-knockout mice

• PCK2 is expressed in human femoral atheroma, suggesting clinical relevance

These findings position PCK2 as a potential therapeutic target for modulating VSMC proliferation in atherosclerosis .

What is the relationship between PCK2 and radioresistance in cancer?

A 2025 study revealed that PCK2 downregulation confers radioresistance in nasopharyngeal carcinoma (NPC) through ferroptosis regulation:

These findings suggest that PCK2 expression levels could serve as a biomarker for radiotherapy response, and that modulating PCK2 might provide new strategies for overcoming radioresistance in cancer treatment .

What are the optimal conditions for PCK2 antibody multiplexing?

When performing multiplexed detection of PCK2 with housekeeping proteins, consider these optimization parameters:

• Anti-PCK2 at 1:75 dilution provides optimal signal when multiplexed with anti-β-actin (1:75)

• For capillary western systems, use 0.5 mm² LCM section with 10 μm thickness as starting material

• PCK2 signal appears at 63 kDa while β-actin appears at 48 kDa

• Signal quantification through area-under-curve calculations provides reliable comparison

• Technical triplicates are recommended for statistical reliability

The figure below shows multiplexing results at different antibody dilutions:

How do PCK2 antibodies perform across different species?

Commercial PCK2 antibodies demonstrate varied cross-reactivity across species:

• The PCK2 Antibody #6924 from Cell Signaling Technology shows reactivity with Human, Mouse, Rat, and Monkey samples

• PCK2 molecular weight may vary slightly by species (63-71 kDa range)

• Species-specific validation is recommended when studying novel model organisms

• Positive controls from well-characterized tissues (kidney, liver) are advisable when testing new species

What are the best approaches for quantifying PCK2 expression changes in disease models?

For accurate quantification of PCK2 expression changes:

• Normalize PCK2 signals to housekeeping proteins (β-actin) using the PCK2/ACTB peak area ratio

• Include technical triplicates for each biological sample

• Use non-parametric t-tests when comparing groups (e.g., healthy vs. disease models)

• For microdissected samples, maintain consistent tissue area (0.25 mm² recommended)

• For Western blotting, load equal protein amounts (30 μg) across samples

This approach has successfully demonstrated statistically significant PCK2 overexpression in diabetic rat Langerhans islets compared to controls (p < 0.05) .

How is PCK2 dysregulation implicated in metabolic disorders?

PCK2 shows altered expression in several metabolic disorders:

• In diabetes: Significantly higher PCK2 expression in Langerhans islets of rats with long-term diabetes compared to normal controls

• In colitis: PCK2 deficiency disrupts intestinal homeostasis through compromised IgA antibody-secreting cell function

• In vascular disease: PCK2 regulates vascular smooth muscle cell proliferation, with implications for atherosclerosis progression

These findings suggest PCK2 as a potential biomarker and therapeutic target across multiple metabolic conditions.

What experimental approaches help delineate PCK2's role in oxidative stress response?

When investigating PCK2's role in redox regulation:

• Monitor glutathione (GSH) levels in PCK2-deficient vs. wild-type cells

• Measure mitochondrial reactive oxygen species (mtROS) production

• Assess TCA cycle flux in relation to PCK2 expression

• Test mitochondria-targeted antioxidants (e.g., Mito-Q) for rescue effects

• Evaluate cell survival/apoptosis markers in oxidative stress conditions

This multi-parameter approach has successfully demonstrated PCK2's protective role against oxidative stress in antibody-secreting cells, with therapeutic implications for inflammatory conditions .

How might targeting PCK2 offer therapeutic potential in inflammatory and metabolic diseases?

Current research suggests several promising therapeutic approaches targeting PCK2:

• For colitis: Antioxidant therapy (particularly mitochondria-targeted compounds like Mito-Q) may mitigate consequences of PCK2 deficiency

• For atherosclerosis: Modulating the Akt-FoxO-PCK2 pathway could inhibit excessive vascular smooth muscle cell proliferation

• For radioresistant cancers: Upregulating PCK2 expression might enhance ferroptosis sensitivity, improving radiotherapy efficacy

• For diabetic complications: Normalizing PCK2 overexpression in pancreatic islets might help restore metabolic balance

These diverse applications highlight PCK2's emerging importance as a therapeutic target across multiple disease contexts.